Summary:
Study:Sunovion SEP361-226
- A Phase 2/3, Randomized, Double-blind, Parallel Group, Placebo-controlled, Flexible-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in the Treatment of Adults With Generalized Anxiety Disorder.
- Age 18-65
- Inclusion Criteria: Primary diagnosis or need of treatment is Generalized Anxiety Disorder
- Must be willing to discontinue psychiatric medications.
- 12 Weeks, 8 visits
- Compensation: Up to $250 per visit
Study: Engrail Therapeutics ENX-102-003
- Randomized, Double-blind, Placebo-controlled Monotherapy Trial to Evaluate the Efficacy and Safety of ENX-102 in Patients with Generalized Anxiety Disorder.
- Age 18-65
- Inclusion Criteria: Primary diagnosis or need of treatment is Generalized Anxiety Disorder
- Must be willing to discontinue psychiatric medications.
- 14 weeks, 13 visits (8 remote visits)
- Compensation: Up to $1,450 for visits and travel.
Study: Cerevel Therapeutics - CVL-865-PA-2001
- Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder.
- Age: 18-65
- Inclusion Criteria: Minimum of 8 panic attacks per month. Panic Disorder should be the main source of treatment. Depression and Anxiety are ok if secondary to Panic Disorder.
- Exclusion Criteria: Lifetime diagnosis of BPAD, PTSD, OCD, Schizophrenia.
- 20 weeks, 12 visits (6 remote visits)
- Compensation: Up to $900 for visits and travel.
Criteria:Study:Sunovion SEP361-226
- Age 18-65
- Inclusion Criteria: Primary diagnosis or need of treatment is Generalized Anxiety Disorder
- Must be willing to discontinue psychiatric medications>
Study: Engrail Therapeutics ENX-102-003
- Age 18-65
- Inclusion Criteria: Primary diagnosis or need of treatment is Generalized Anxiety Disorder
- Must be willing to discontinue psychiatric medications.
Study: Cerevel Therapeutics - CVL-865-PA-2001
- Age: 18-65
- Inclusion Criteria: Minimum of 8 panic attacks per month. Panic Disorder should be the main source of treatment. Depression and Anxiety are ok if secondary to Panic Disorder.
- Exclusion Criteria: Lifetime diagnosis of BPAD, PTSD, OCD, Schizophrenia.
Qualified Participants May Receive:
Study:Sunovion SEP361-226
- 12 Weeks, 8 visits
- Compensation: Up to $250 per visit
- Study medication and care at no cost. No insurance required.
Study: Engrail Therapeutics ENX-102-003
- 14 weeks, 13 visits (8 remote visits)
- Compensation: Up to $1,450 for visits and travel.
- Study medication and care at no cost. No insurance required.
Study: Cerevel Therapeutics - CVL-865-PA-2001
- 20 weeks, 12 visits (6 remote visits)
- Compensation: Up to $900 for visits and travel.
- Study medication and care at no cost. No insurance required.